SCHEMBL29845321

SCHEMBL29845321

O=C(O)N1Cc2c(cccc2-c2ccncc2)C1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHPS P49366 2/20 0.45
UCHL1 P09936 1/20 0.38
PIK3CD O00329 1/20 0.37
CYP3A4 P08684 1/20 0.37
AKT1 P31749 1/20 0.37
PIK3CA P42336 1/20 0.37
PIK3CB P42338 1/20 0.37
PIK3CG P48736 1/20 0.37
LMNA P02545 1/20 0.36
ALDH1A1 P00352 3/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
NPC1 O15118 1/20 0.36
TP53 P04637 1/20 0.36
MAPT P10636 1/20 0.36
RAB9A P51151 1/20 0.36
MAPK10 P53779 1/20 0.36
HSD17B10 Q99714 1/20 0.36
PDCD1 Q15116 1/20 0.35
CD274 Q9NZQ7 1/20 0.35
CYP46A1 Q9Y6A2 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30701033 0.80 BUB1 (0.43) DHPSUCHL1PIK3CA
SCHEMBL31303406 0.75 GRM1 (0.40) DHPSLMNAALDH1A1SMN1; SMN2MAPT
SCHEMBL14352147 0.73 DHPS (0.40) DHPSPIK3CDALDH1A1SMN1; SMN2CYP46A1
Trifluoroacetic Acid SCHEMBL14362107 0.73 DHPS (0.38) DHPSCYP46A1ADORA2AADORA2BKDR
SCHEMBL29736672 0.72 MAP4K1 (0.41) DHPS
SCHEMBL31458945 0.72 NOTUM (0.43)
SCHEMBL14862910 0.70 ABHD6 (0.53) UCHL1LMNACYP46A1CDK4CCND1
SCHEMBL29736418 0.69 NPSR1 (0.42) CYP3A4ALDH1A1SMN1; SMN2MAPTKDM4E
SCHEMBL2065531 0.67 KDM4E (0.57) CYP3A4LMNAALDH1A1SMN1; SMN2NPC1
SCHEMBL29606824 0.67 KDM4E (0.57) CYP3A4LMNAALDH1A1SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240199603-A1 HPK1 ANTAGONISTS AND USES THEREOF SCHRÖDINGER, INC. 2024-06-20 US disclosed
US-11926625-B2 HPK1 antagonists and uses thereof Nimbus Saturn, Inc. (US) 2024-03-12 US disclosed
EP-4301756-A1 HPK1 ANTAGONISTS AND USES THEREOF Nimbus Saturn, Inc. (US) 2024-01-10 EP disclosed
US-20230117631-A1 HPK1 ANTAGONISTS AND USES THEREOF Nimbus Saturn, Inc. 2023-04-20 US disclosed
WO-2022187856-A1 HPK1 ANTAGONISTS AND USES THEREOF Nimbus Saturn, Inc. (US) 2022-09-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240199603-A1 HPK1 ANTAGONISTS AND USES THEREOF PDXK, HIPK1, PCK1 DHPS 1487/4885UCHL1 4480/4885PIK3CD 2012/4885
US-20230117631-A1 HPK1 ANTAGONISTS AND USES THEREOF PDXK, HIPK1, PCK1 DHPS 1487/4885UCHL1 4480/4885PIK3CD 2012/4885
US-11926625-B2 HPK1 antagonists and uses thereof PDXK, HIPK1, PCK1 DHPS 1487/4885UCHL1 4480/4885PIK3CD 2012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.